BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Modlin IM, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab. 2016;30:59-77. [PMID: 26971844 DOI: 10.1016/j.beem.2016.01.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Nanayakkara J, Tyryshkin K, Yang X, Wong JJM, Vanderbeck K, Ginter PS, Scognamiglio T, Chen YT, Panarelli N, Cheung NK, Dijk F, Ben-Dov IZ, Kim MK, Singh S, Morozov P, Max KEA, Tuschl T, Renwick N. Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining. NAR Cancer 2020;2:zcaa009. [PMID: 32743554 DOI: 10.1093/narcan/zcaa009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Paraneoplastic endocrine syndromes. Endocrine-Related Cancer 2017;24:R173-90. [DOI: 10.1530/erc-17-0036] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
3 Tran CG, Sherman SK, Howe JR. Small Bowel Neuroendocrine Tumors. Curr Probl Surg 2020;57:100823. [PMID: 33234227 DOI: 10.1016/j.cpsurg.2020.100823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A. Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. PLoS One 2017;12:e0188876. [PMID: 29232390 DOI: 10.1371/journal.pone.0188876] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
5 Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8:761-773. [PMID: 28382138 DOI: 10.7150/jca.17648] [Cited by in Crossref: 505] [Cited by in F6Publishing: 492] [Article Influence: 101.0] [Reference Citation Analysis]
6 Chen L, Zhang Y, Lin Y, Deng L, Feng S, Chen M, Chen J. The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. Clin Biochem 2017;50:982-7. [PMID: 28668469 DOI: 10.1016/j.clinbiochem.2017.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
7 Kalligeros M, Diamantopoulos L, Toumpanakis C. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review. Biology (Basel) 2021;10:950. [PMID: 34681049 DOI: 10.3390/biology10100950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Clift AK, Frilling A. Liver-Directed Therapies for Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:44. [PMID: 33721122 DOI: 10.1007/s11912-021-01030-0] [Reference Citation Analysis]
9 Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocr Relat Cancer 2019;26:R157-79. [PMID: 30615596 DOI: 10.1530/ERC-18-0354] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
10 Panarelli N, Tyryshkin K, Wong JJM, Majewski A, Yang X, Scognamiglio T, Kim MK, Bogardus K, Tuschl T, Chen Y, Renwick N. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. Endocrine-Related Cancer 2019;26:47-57. [DOI: 10.1530/erc-18-0244] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
11 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
12 Pedraza-Arévalo S, Gahete MD, Alors-Pérez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 2018;19:179-92. [PMID: 30293213 DOI: 10.1007/s11154-018-9465-0] [Reference Citation Analysis]
13 Jeune F, Taibi A, Gaujoux S. Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors. Scand J Surg. 2020;109:42-52. [PMID: 31975647 DOI: 10.1177/1457496919900417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Freis P, Graillot E, Rousset P, Hervieu V, Chardon L, Lombard-Bohas C, Walter T. Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers. Sci Rep. 2017;7:40609. [PMID: 28074897 DOI: 10.1038/srep40609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
15 Laskaratos F, Caplin M. Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours. European Journal of Surgical Oncology 2019;45:52-9. [DOI: 10.1016/j.ejso.2018.03.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Pedraza-Arévalo S, Gahete MD, Alors-Pérez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 2018;19:179-92. [PMID: 30293213 DOI: 10.1007/s11154-018-9465-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
17 van Faassen M, Bouma G, de Hosson LD, Peters MAM, Kats-Ugurlu G, de Vries EGE, Walenkamp AME, Kema IP. Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors. Clin Chem 2019;65:1388-96. [PMID: 31551315 DOI: 10.1373/clinchem.2019.305359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Cidon EU. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol 2017; 9(1): 4-20 [PMID: 28144395 DOI: 10.4251/wjgo.v9.i1.4] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
19 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Reference Citation Analysis]
20 Virarkar M, Vulasala SS, Morani AC, Waters R, Gopireddy DR, Kumar S, Bhosale P, Lall C. Neuroendocrine Neoplasms of the Gynecologic Tract. Cancers (Basel) 2022;14:1835. [PMID: 35406607 DOI: 10.3390/cancers14071835] [Reference Citation Analysis]
21 Clift AK, Frilling A. Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. World J Gastroenterol 2018; 24(20): 2152-2162 [PMID: 29853733 DOI: 10.3748/wjg.v24.i20.2152] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
22 Lv Y, Pu N, Mao W, Chen W, Wang H, Han X, Ji Y, Zhang L, Jin D, Lou W, Xu X. Development of predictive prognostic nomogram for NECs of rectum on population-based exploration. Endocr Connect 2018:/journals/ec/aop/ec-18-0353. [PMID: 30352397 DOI: 10.1530/EC-18-0353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Carcinoid Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol 2019;20:70. [PMID: 31286272 DOI: 10.1007/s11864-019-0671-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
24 Gugliandolo A, Rajan TS, Scionti D, Diomede F, Bramanti P, Mazzon E, Trubiani O. Reprogramming of Oncogene Expression in Gingival Mesenchymal Stem Cells Following Long-Term Culture In Vitro. Cellular Reprogramming 2017;19:159-70. [DOI: 10.1089/cell.2016.0056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Reference Citation Analysis]
26 Ewang-emukowhate M, Nair D, Caplin M. The role of 5-hydroxyindoleacetic acid in neuroendocrine tumors: the journey so far. International Journal of Endocrine Oncology 2019;6:IJE17. [DOI: 10.2217/ije-2019-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
27 Woltering EA, Voros BA, Thiagarajan R, Beyer DT, Ramirez RA, Wang YZ, Mamikunian G, Boudreaux JP. Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel. Pancreas 2018;47:843-8. [PMID: 29939909 DOI: 10.1097/MPA.0000000000001092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Kan J, Tian Y, Shao Y, Xu H, Li X, Tang Q. Role of the ratio of NSE serum concentration in evaluating the therapeutic effect on metastatic neuroendocrine neoplasms of the liver. Tumori 2021;:3008916211002272. [PMID: 33759643 DOI: 10.1177/03008916211002272] [Reference Citation Analysis]
29 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
30 Fiorio Pla A, Gkika D. Ca2+ Channel Toolkit in Neuroendocrine Tumors. Neuroendocrinology 2020;110:147-54. [PMID: 31177261 DOI: 10.1159/000501397] [Reference Citation Analysis]
31 Haider M, Jiang BG, Parker JA, Bullock AJ, Goehler A, Tsai LL. Use of MRI and Ga-68 DOTATATE for the detection of neuroendocrine liver metastases. Abdom Radiol (NY) 2022;47:586-95. [PMID: 34757459 DOI: 10.1007/s00261-021-03341-z] [Reference Citation Analysis]
32 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
33 Liu X, Han Z, Yang C. Associations of microRNA single nucleotide polymorphisms and disease risk and pathophysiology. Clin Genet 2017;92:235-42. [PMID: 27925170 DOI: 10.1111/cge.12950] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
34 Frey S, Mirallié E, Le Bras M, Regenet N. What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review. Cancers (Basel) 2021;13:5954. [PMID: 34885063 DOI: 10.3390/cancers13235954] [Reference Citation Analysis]
35 Cruz-Hernández E, Mahmood U, Golia Pernicka JS, Paroder V, Petkovska I, Gollub MJ, Shia J, Ganesh K, Bates DDB. Initial evaluation of dual-energy computed tomography as an imaging biomarker for hepatic metastases from neuroendocrine tumor of the gastrointestinal tract. Quant Imaging Med Surg 2021;11:2085-92. [PMID: 33936989 DOI: 10.21037/qims-20-917] [Reference Citation Analysis]
36 Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
37 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
38 Tran CG, Sherman SK, Scott AT, Ear PH, Chandrasekharan C, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:732-41. [PMID: 32656719 DOI: 10.1245/s10434-020-08784-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Malczewska A, Oberg K, Kos-Kudla B. NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocr Connect 2021;10:110-23. [PMID: 33289691 DOI: 10.1530/EC-20-0417] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Reference Citation Analysis]
41 Sreekumar A, Saini S. Role of MicroRNAs in Neuroendocrine Prostate Cancer. ncRNA 2022;8:25. [DOI: 10.3390/ncrna8020025] [Reference Citation Analysis]
42 Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, Appetecchia M. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers (Basel) 2019;11:E1113. [PMID: 31382663 DOI: 10.3390/cancers11081113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
43 Streuli J, Harris AG, Cottiny C, Allagnat F, Daly AF, Grouzmann E, Abid K. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors. Neuropeptides 2018;68:84-9. [PMID: 29523357 DOI: 10.1016/j.npep.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
45 Yu R. Interpretation of Unexpectedly High Levels of Endocrine Tumor Markers. Endocr Pract 2018;24:841-7. [PMID: 30106635 DOI: 10.4158/EP-2018-0166] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Duan K, Mete O. Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers: Duan and Mete. Cancer Cytopathology 2016;124:871-84. [DOI: 10.1002/cncy.21765] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
47 Jiménez B, Abellona U MR, Drymousis P, Kyriakides M, Clift AK, Liu DSK, Rees E, Holmes E, Nicholson JK, Kinross JM, Frilling A. Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility. Cancers (Basel) 2021;13:374. [PMID: 33498434 DOI: 10.3390/cancers13030374] [Reference Citation Analysis]
48 Dillon JS. Workup of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:165-83. [PMID: 32151354 DOI: 10.1016/j.soc.2019.10.002] [Reference Citation Analysis]
49 Robbins HL, Symington M, Mosterman B, Tranter F, Davies L, Randeva HS, Penedo A, Ferreira C, Darby C, Grammatopoulos D, Kaltsas G, Weickert MO. Effects of intake of breakfast or caffeine-containing beverages on measurement of circulating chromogranin A in plasma. GastroHep 2019;1:11-21. [DOI: 10.1002/ygh2.208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Mandair D, Khan MS, Lopes A, Furtado O’mahony L, Ensell L, Lowe H, Hartley JA, Toumpanakis C, Caplin M, Meyer T. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism 2021;106:872-82. [DOI: 10.1210/clinem/dgaa822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
51 Sagum J, Yu R. False-Positive Pancreastatin Results From a Commercial Laboratory: A Report of 2 Cases. Pancreas 2021;50:e33-5. [PMID: 33835984 DOI: 10.1097/MPA.0000000000001774] [Reference Citation Analysis]